Working to find solutions through collaborations
Biogen’s corporate headquarters is located in the center of the Boston-area academic community. We enjoy ties with many of the area’s world-class universities, and we also partner with leading academic institutions globally. We believe that collaborations between Biogen scientists and academic researchers are critical to maintaining a vibrant research and development program, and we continuously work to establish new partnerships and consortia that focus on a range of disease mechanisms and targets. Together, we collaborate on research, creating and comparing data and insights to tackle complex challenges that a single institution might not be able to solve on its own.
UNIVERSITY OF PENNSYLVANIA
This multi-year collaboration between Biogen and the University of Pennsylvania aims to advance gene therapy and gene editing technologies that focus on therapeutic approaches that target the eye, skeletal muscle and the central nervous system. This alliance will also explore next-generation gene transfer technology and genome editing as a potential therapeutic platform.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY/WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Biogen is working in close collaboration with Whitehead Institute researchers to pioneer novel ways to improve human health through basic biomedical research in the areas of immunology, neurology, developmental biology, genetics and genomics.
HARVARD MEDICAL SCHOOL/RUBIN LABORATORY
We are working with Harvard researchers on exciting early-stage projects. These include mapping human protein interactions to yield new insights, pathways and targets for a wide range of diseases; modeling system genetics to identify new pathways for Parkinson’s disease; and investigating methods of action for spinal muscular atrophy, amyotrophic lateral sclerosis and Parkinson’s disease in conjunction with the Rubin Laboratory.
Biogen and several leading academic research centers have formed a consortium dedicated to identifying new approaches for treatment of amyotrophic lateral sclerosis (ALS). The consortium includes Yale University, Harvard University, Columbia University and The Rockefeller University.
DUKE UNIVERSITY/HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGY
In coordination with the ALS Consortium, we worked with these two premier research institutions to sequence the genomes of nearly 3,000 patients with amyotrophic lateral sclerosis (ALS). This project, which screened the largest number of ALS patients in a single study, identified a new gene associated with ALS.
This multiyear collaboration between Biogen and Columbia will enable Biogen and Columbia to investigate the genomes of patients showing unusual treatment responses or unique disease presentations and to explore the connections among genes, pathways, and disease processes.
LAWRENCE BERKELEY NATIONAL LAB/UNIVERSITY OF CONNECTICUT (UCONN) HEALTH CENTER
Biogen, the Berkeley Lab and UCONN Health Center are investigating RNA-binding protein sequencing to identify essential functional modules between ribonucleoprotein complexes and RNA. We are using this data to explore interactions relevant to neurodegeneration, with a focus on determining its cause.
Biogen’s immunology group created this consortium to investigate the underlying pathogenesis of scleroderma. Investigators from Tufts University, Yale University, University of Pennsylvania, University of Utrecht and the University of Glasgow — all representing different fields of immunology — will coordinate their research activities and collaborate with Biogen scientists to identify new targets with potential for therapeutic intervention.
Biogen initiated a collaboration with investigators from Harvard University, Yale University, University of Pennsylvania, University of California, San Francisco, and Boston University to identify and validate targets in fibrosis and regeneration.
The new epigenetics hub at Biogen has engaged in a multiyear partnership with experts at Harvard University, Washington University, College de France, Institut Curie, and MIT, to investigate the role of histones, noncoding RNAs and mechanisms of DNA modification in neurodegeneration and regeneration.
ACCELERATING MEDICINES PARTNERSHIP
Through this partnership, Biogen is collaborating with the National Institutes of Health, nine other biopharmaceutical companies and several nonprofit disease foundations to transform the current model for identifying and validating promising biological targets of disease. Collectively the program will explore new diagnostics and drug development for Alzheimer’s disease, type 2 diabetes, rheumatoid arthritis and lupus. Biogen is specifically focusing on Alzheimer’s disease. All of the data and analyses generated from this partnership will be made publicly available, exponentially increasing the biomedical community’s resources, knowledge and, ultimately, ability to effectively fight disease.